We further demonstrate the clinically relevant potential of GSK-3 inhibitors as antileukemic agents and extend the field of application of such agents. Indeed, although APL patients benefit ...

In a notable study, researchers designed and synthesized novel compounds that act as dual inhibitors targeting both glutaminyl cyclase and glycogen synthase kinase-3β (GSK-3β), another enzyme ...

GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...

That is below the 30% rate reported at an interim stage of the study at the International Liver Congress earlier this year, but still sufficient for GSK to take the drug forward into a phase 3 ...

which was acquired by GSK when it took over Tesaro in a $5.1 billion deal agreed in 2019, along with PARP inhibitor Zejula (niraparib). There are a number of other TIM-3 targeting drugs coming ...

Depemokimab is an inhibitor of IL-5 ... for treating eosinophilic granulomatosis with polyangiitis. GSK has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank ...